Discovery of a Novel Tripeptide Linker that Broadens the Therapeutic Window of Auristatin-Based Antibody–Drug Conjugates by Reducing Bone Marrow Toxicity
Open Access
- 23 July 2026
- journal article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
Abstract
No abstract availableThis publication has 32 references indexed in Scilit:
- Treatment‐related adverse events of antibody–drug conjugates in clinical trials: A systematic review and meta‐analysisCancer, 2022
- Discovery of BT8009: A Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of CancerJournal of Medicinal Chemistry, 2022
- Strategies to Optimize Peptide Stability and Prolong Half-Life2022
- Enzyme-Agnostic Lysosomal Screen Identifies New Legumain-Cleavable ADC LinkersBioconjugate Chemistry, 2021
- Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody–Drug ConjugatesBioconjugate Chemistry, 2021
- Tailored Linker Chemistries for the Efficient and Selective Activation of ADCs with KSPi PayloadsBioconjugate Chemistry, 2020
- Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylationToxicology and Applied Pharmacology, 2020
- SPOT Synthesis: The Solid-Phase Peptide Synthesis on Planar Surfaces2019
- Clinical toxicity of antibody drug conjugates: a meta-analysis of payloadsInvestigational New Drugs, 2017
- Spot-synthesis: an easy technique for the positionally addressable, parallel chemical synthesis on a membrane supportTetrahedron, 1992